Bayer Aktiengesellschaft (BAYRY)
POSITIVEPrice
$36.19
Market Cap
$35.55B
Fundamental
65
Technical
85
Composite
71
AI Analysis
Generated on demand using your Gemini API key
Gemini API key not configured
Add your Gemini API key in Settings to unlock AI analysis.
Overview
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Balance Sheet & Liquidity
Revenue
$45.58B
Net Income
$-3.62B
Free Cash Flow
$7.31B
Total Equity
$28.84B
Total Liabilities
$38.89B
Current Ratio
1.05
Interest Coverage
-
Debt/EBITDA
3.83
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Fair Value Estimation
UndervaluedFair Value
$62.39
Current Price
$36.19
Margin of Safety
+42.0%
Fair Value Range
$40.56 - $84.23
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-6.9%
P/B Ratio
1.23
P/FCF
4.86
Gross Margin
59.9%
ROIC
13.9%
Value Creation (Economic Moat)
ROIC
13.9%
WACC
4.6%
ROIC − WACC
+9.3 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (11)
- ROIC 13.9%
- Gross Margin 59.9%
- P/FCF 4.86
- P/B Ratio 1.23
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Analyst Consensus 75% Buy
- Earnings Surprise avg 36.1%
Failed (6)
- Price CAGR -9.73%
- CapEx intensity
- ROE -7.5%
- Revenue Growth 5Y 1.9%
- Net Margin Trend -7.9% vs -5.5%
- Piotroski F-Score 2/9
Unavailable (10)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Price Chart
Technical Indicators
RSI (14)
45.54
SMA 50
$38.14
SMA 200
$35.51
MACD
0.02
Volatility
2.4%
Momentum (12m)
31.2%
RSI 45.5, SMA trend bullish, momentum 31.2%.
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. William N. Anderson | Chairman of the Management Board & CEO | 59 |
| Mr. Stefan Oelrich | Head of the Pharmaceuticals Division & Member of the Board of Management | 57 |
| Ms. Heike Prinz | Chief Talent Officer, Labor Director & Member of Management Board | 61 |
| Dr. Judith Hartmann | CFO & Member of Management Board | 56 |
| Mr. Rodrigo Santos | Member of Management Board, Head of the Crop Science Division & President of Crop Science Division | 52 |
| Mr. Julio Triana | Member of Management Board & President of Consumer Health Division | 60 |
| Mr. Alex Buschermohle | Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division | - |
| Dr. Jost Reinhard | Senior VP & Head of Investor Relations | 53 |
| Mr. Bill Dodero | General Counsel and Senior VP of Law Patents & Compliance | - |
| Mr. Michael Preuss | Head of Communications, Government Relations and Corporate Brand | - |
Audit Risk
6
Board Risk
1
Compensation Risk
2
Shareholder Rights Risk
1
Latest News
Recent headlines for BAYRY, sourced from Markets Gazette.